Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker,
losartan, in patients with Sickle Cell Disease (SCD) 6 years or older for 12 months. The
investigators will enroll 24 patients with SCD over the course of 1 year with a goal to
complete all study procedures in 2 years. The short-term goal is to obtain clinical pilot
data regarding the safety and efficacy of losartan in stabilizing or decreasing extracellular
volume fraction (ECV) after 12 months of therapy.